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Abstract 
 
Background: Cognitive impairment is prevalent, disabling, and poorly managed in persons with 
MS. To date, two studies have identified aerobic capacity as a correlate of cognition in MS, but 
there has yet to be an investigation of multiple domains of fitness as correlates of cognition in 
this population. Such an examination is important for identifying the appropriate modes of 
exercise training for possibly improving cognition. 
 
Objective: This study examined the relationships among aerobic capacity, muscle strength, and 
balance with cognitive function in persons with MS. 
 
Methods: 31 persons with MS and 31 controls matched by age, height, weight, and sex 
completed two neuropsychological measures of cognitive processing speed (PASAT and 
SDMT). Participants underwent an incremental exercise test to exhaustion on a cycle ergometer 
as a measure of aerobic capacity; three maximal isometric extensions and one maximal isometric 
flexion with each knee on an isokinetic dynamometer at three different joint angles as a measure 
of muscular strength; and stood on a force platform without shoes for 30 seconds with eyes open 
to measure postural sway.  
 
Results: Independent samples t-tests indicated that MS and control groups differed in PASAT 
score (t = −2.13, p = .04), SDMT score (t = −2.69, p = .01), aerobic capacity (t = −2.99, p < .01), 
and balance (t = 4.06, p < .01), but not in muscular strength. Cognitive processing speed was 
significantly associated with aerobic capacity (r = .43 and .44) and balance (r= −.52 and −.52), 
but not muscular strength in the overall and MS samples, respectively. Lastly, hierarchical 
iii 
regression analysis indicated that aerobic capacity (β = .27) and balance (β = −.40) accounted for 
differences in cognitive processing speed between MS and control groups. 
 
Conclusions: Aerobic capacity and balance, but not muscular strength, are associated with 
cognitive processing speed in persons with MS, suggesting that aerobic exercise and balance 
training are avenues for possibly improving cognitive impairment in this population.
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Chapter 1—Introduction 
 
Multiple sclerosis (MS) can be described as a non-traumatic neurodegenerative disease 
with an estimated prevalence of 1 per 1000 people in the United States (Mayr, et al., 2003; 
Wallin, Page, & Kurtzke, 2000).  This disease is initially characterized by immune-mediated, 
multi-focal demyelination in white matter of the brain and spinal cord (Mitchell, Benito-Leon, 
Gonzalez, & Rivera Navarro, 2005; Trapp & Nave, 2008). The disease process eventually causes 
damage of both grey and white matter in the brain, resulting in the accumulation of both physical 
and cognitive disability.   
There is increasing evidence that cognitive impairment is prevalent and poorly managed 
in persons with MS.  In studies involving neuropsychological testing, an estimated 45-65% of 
individuals with MS experience cognitive impairment as a prominent symptom (Bobholz & Rao, 
2003; Prakash et al., 2007).  This impairment is often seen in domains of working memory, 
processing speed, and executive control (Prakash et al., 2007).  There is no FDA-approved 
treatment for cognitive impairment in MS, and trials of pharmacological agents (e.g. modafinil, 
L-amphetamine, donepezil) as well as studies involving cognitive rehabilitation generally have 
been conflicting and disappointing (Amato, Portaccio & Zipoli, 2006; Morrow et al., 2009; 
Stankoff et al., 2005).   
Exercise training might represent a behavioral approach for managing cognitive 
dysfunction in MS.  This is based on emerging interest by researchers and clinicians in the 
effects of fitness (i.e., characteristics of an individual reflecting aerobic capacity, muscular 
strength, balance, agility, etc.) and exercise (i.e., planned behavior aimed towards improving an 
individual’s fitness) on cognition in persons with MS (Motl, Sandroff, & Benedict, 2011).  
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Indeed, two studies have examined cardiorespiratory fitness (a presumed surrogate of aerobic 
exercise training) as a correlate of cognitive function in MS (Prakash et al., 2007; 2010), and two 
studies have examined the effects of exercise training on cognition (Oken et al., 2004; Romberg, 
Virtanen & Ruutiainen, 2005).  Cardiorespiratory fitness, in one study, was associated with faster 
reaction times on the PVSAT (a valid measure of sustained attention, processing speed, and 
working memory in persons with MS), greater activation of the right inferior frontal gyrus and 
middle frontal gyrus (regions of the cerebral cortex), and less activation of the anterior cingulate 
cortex (Prakash, 2007). The other study reported that cardiorespiratory fitness was positively 
associated with both white and grey matter integrity and processing speed in persons with MS 
and healthy controls (Prakash, 2010).  By comparison, neither aerobic exercise training, 
resistance exercise training, nor yoga improved cognition in MS (Oken et al., 2004; Romberg, 
2005).  Such null results from the training studies highlight the importance of considering the 
well-established gerontological literature (Hillman, Erickson, & Kramer, 2008) as a way of 
better informing examinations of fitness, exercise training, and cognition in MS.  
Fitness and exercise training have been associated with better cognitive performance in 
older adults (a population who commonly experiences cognitive decline).  One meta-analysis 
reported that exercise training was associated with overall better performance on cognitive tasks 
with an average effect size of 0.478 standard deviations (Colcombe & Kramer, 2003).  
Interestingly, the moderator analysis indicated that combined exercise training (both strength and 
aerobic training) was associated with greater improvements in cognition than aerobic training 
alone (Colcombe, 2003).  Other studies have reported that cardiorespiratory fitness, muscle 
strength, and balance, respectively, are associated with better cognitive function in older adults 
(Newson & Kemps, 2008; Boyle et al., 2009; Voelcker-Rehage, Godde, & Staudinger, 2010).  
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This would suggest that cardiorespiratory fitness, muscle strength, and balance have the potential 
for independent contributions towards combating cognitive impairment in older adults and 
perhaps MS. 
 The gerontology literature provides a backdrop for the current study of fitness and 
cognition in MS by indicating that different types of fitness and modes of training are important 
when developing interventions to maximize cognitive benefits.  The purpose of this study, 
therefore, was to examine the relationships among cardiorespiratory fitness, muscle strength, and 
balance as components of fitness and cognitive function in MS.  This examination of fitness will 
inform the development of subsequent exercise training interventions aimed at improving 
cognition in individuals with MS.  First, we examined group differences in fitness and cognition 
among persons with MS and healthy controls; we then evaluated which domains of fitness were 
associated with cognition in the overall, MS, and control samples, separately; and finally, we 
examined fitness as a mediator of group differences in cognition and identified the independent 
contributions of fitness variables for explaining such differences in cognition. Accordingly, the 
first hypothesis was that there would be significant differences in fitness and cognition between 
persons with MS and healthy controls. The second hypothesis was that cardiorespiratory fitness, 
muscular strength, and balance would each be associated with cognition in persons with MS, and 
that cardiorespiratory fitness would have the strongest association, based on findings from the 
gerontology literature. The third hypothesis was that all three domains of physical fitness would 
explain group differences in cognition between persons with MS and healthy controls (i.e., 
mediation).  
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Chapter 2—Review of Literature 
EPIDEMIOLOGY OF MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) can be described as a non-traumatic neurodegenerative disease 
that typically presents in the 3rd or 4th decade of life (Wallin, Page, & Kurtzke, 2000; Mayr et al., 
2003). As of the year 2000, median age of diagnosis was reported to be 37.2 years (Mayr, 2003).  
Median survival has been reported as between 30-43 years following diagnosis of MS (Wallin, 
2000).  In terms of sex differences, women are affected nearly three times more often than men 
(Noonan, Kathman, & White, 2002).  Global incidence of MS peaks at about 30 years of age 
(Koch-Henriksen & Sorenson, 2010), and raw incidence rates have been reported to range from 
0.86 per 100,000 person-years to 12.2 per 100,000 person-years (Mayr, 2003).   
According to a systematic review of epidemiological studies across the globe (Koch-
Henriksen, 2010), MS has been reported to have the highest prevalence estimates in Western 
Europe and North America, followed by areas in Central and Eastern Europe, the Balkans, and 
Australia/New Zealand.  Regions with the lowest prevalence estimates included Asia, the Middle 
East, and Africa (Koch-Henriksen, 2010).  Accordingly, MS is more common in individuals with 
northern European ancestry than those with Hispanic, African, or Asian descent (Williamson, 
2007; Mayr, 2003).  In the United States, multiple sclerosis has an estimated prevalence of 1 per 
1000 people (Wallin, 2000; Mayr, 2003; Koch-Henriksen, 2010; Williamson, Henry, Schiffer, & 
Wagner, 2007; Noonan, 2002).  Within the United States, geographically, MS is most prevalent 
in the northern states with lower prevalence in southern states (Wallin, 2000; Williamson, 2007). 
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CLINICAL DISEASE COURSE 
There are relapsing and progressive presentations of multiple sclerosis.  Approximately 
85% of those with MS experience a disease course consisting of periodic neurological 
exacerbations, or relapses, followed by periods of relatively stable neurological function.  This 
biphasic pattern is termed relapsing-remitting multiple sclerosis (RRMS) (Trapp, 2008; Smith & 
McDonald, 1999; Vollmer, 2007; Mitchell, Benito-Leon, Morales Gonzalez, Rivera-Navarro, 
2005).  These relapses are attributed to instances of acute inflammation in the central nervous 
system which cause damage to myelinated axons and neurons (Vollmer, 2007), subsequently 
hindering neuronal conduction.  In the period following this acute inflammation (i.e., remission 
phase), growth factors promote remyelination of damaged axons in the CNS (Vollmer, 2007; 
Smith, 1999).  These axons undergoing remyelination can regain the ability to conduct, albeit 
often in a diminished capacity.  Over time, the ability for growth factors to remyelinate damaged 
axons following a relapse decreases, leading to neuronal degeneration and eventual irreversible 
neurological disability (Vollmer, 2007).    
After a period of 8-20 years, a majority of persons with RRMS experience a new disease 
course consisting of irreversible neurological impairment, termed secondary progressive MS 
(SPMS) (Trapp, 2008; Smith, 1999; Vollmer, 2007).  Additionally, 15% of individuals 
diagnosed with MS have a disease course that presents with immediate irreversible neurological 
damage, termed primary progressive MS (PPMS) (Trapp, 2008; Smith, 1999).  PPMS is 
generally later onset than RRMS, and both progressive disease courses have been linked to 
axonal degeneration (Trapp, 2008; Smith, 1999).   
Axonal degradation, which is initially triggered by chronic demyelination associated with 
progressive MS, leads to irreversible neurological disability (Vollmer, 2007; Trapp, 2008; Smith, 
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1999).  A major goal of treatment for MS is to prevent relapses (i.e., limit chronic demyelination) 
in order to delay this progression from demyelination to degeneration (Vollmer, 2007).  Two 
mechanisms have been proposed to explain how axonal degeneration occurs in MS.  The first 
mechanism involves axonal degeneration following chronic demyelination due to inadequate 
trophic support, provided by oligodendrocytes (Trapp, 2008).  The other proposed mechanism 
for this degenerative process is that following chronic demyelination, axons become degenerated 
due to increases in intracellular calcium (Ca2+), which eventually leads to axonal loss (Trapp, 
2008).  Recent studies have found that this neurodegeneration occurs in both white and grey 
matter of the brain and spinal cord (Trapp, 2008; Smith, 1999).  Prominent areas of cortical 
atrophy in the brain include the cingulate gyrus, and insular, frontal, temporal, and parietal 
cortices, with less degeneration occurring in the primary motor, sensory, and visual cortices 
(Trapp, 2008). 
 
SYMPTOMS OF MULTIPLE SCLEROSIS 
The immune-mediated loss of axons in both white and grey matter in various locations of 
the brain and spinal cord can lead to a variety of symptoms in individuals with multiple sclerosis.  
The presentation of symptoms of MS is reflected by the location of lesions in the central nervous 
system (Lublin, 2007; Vollmer, 2007).  The worsening of symptoms over time can occur in 
either a step-wise (i.e., incomplete recovery from relapses) or a progressive fashion (Lublin, 
2007).  Initial symptoms of MS often manifest as sensory disturbances, such as Lhermitte’s sign, 
an electrical sensation running down the spine that accompanies neck flexion (Schapiro, 2005; 
Mitchell, 2005; Smith, 1999).  These sensory disturbances often involve lesions of the spinal 
cord, optic nerve, brainstem, or cerebellum (Lublin, 2007).   
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Fatigue has been identified as the most common and disabling symptom of MS, and 
presents as an overwhelming feeling of tiredness during activities of daily life (Schapiro, 2005; 
Hadjimichael, Vollmer, & Oleen-Burkey, 2008).  74% of persons with MS have reported fatigue 
to be a prominent symptom of the disease, with 15-40% of individuals reporting fatigue to be the 
most disabling symptom (Hadjimichael, 2008).  Fatigue has been associated with both mobility 
disability and disease severity (Hadjimichael, 2008).  Spasticity, defined as a velocity-dependent 
stiffness about a joint, is another debilitating symptom of MS (Schapiro, 2005).  53% of persons 
with MS report experiencing mild to severe spasticity (Rizzo, Hadjimichael, Preiningerova, & 
Vollmer, 2004).  Severe spasticity has been associated with more progressive forms of MS and 
worse disability (Rizzo, 2004).  Many individuals with MS report sensitivity to heat, which is 
thought to exacerbate axonal conduction block associated with periods of inflammatory 
demyelination (Smith, 1999).  Postural instability and impaired coordination have also been 
reported as major disturbances in individuals with MS (Schapiro, 2005).  Ambulatory 
impairment is another hallmark symptom of MS associated with decreased quality of life in MS 
(Pittock et al., 2004), and is a major component of the Expanded Disability Disease Status scale, 
a clinical measure of disease severity (Pittock, 2004). Optic neuritis has also been associated 
with multiple sclerosis.  13-85% of patients who experience optic neuritis have been diagnosed 
with MS (Ebers, 1985).   Bladder and bowel dysfunction have been identified as common 
symptoms of MS as well, with 56% of persons with MS reporting bladder dysfunction and 52% 
reporting bowel dysfunction (Chia et al., 1995).  Finally, psychological disorders have been 
associated with MS, such as anxiety, depression, and cognitive impairment (Mitchell, 2005). 
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COGNITIVE DYSFUNCTION IN MS 
Cognitive impairment is common and debilitating in multiple sclerosis. In studies 
involving neuropsychological testing, an estimated 45-65% of individuals with MS experience 
cognitive impairment as a prominent symptom (Bobholz & Rao, 2003).  Cognitive dysfunction is 
prevalent in the three main disease courses of MS (e.g., RRMS, SPMS, and PPMS), and can 
often affect individuals in the earliest stages of MS, including clinically isolated syndrome (CIS), 
even prior to a definite diagnosis of multiple sclerosis (Denney, Sworowski, & Lynch, 2005; 
Achiron & Barak, 2006).  Further, cognitive impairment can affect an individual with MS 
without the presentation of physical disability (Achiron, 2006; Schulz, Kopp, Kunkel, & Feiss, 
2006; Calabrese, 2006).  In persons with MS, this dysfunction can negatively impact activities of 
daily life, such as driving a car (Bobholz, 2003), remembering important information, and 
multitasking (Mohr & Cox, 2001).  Cognitive impairment in individuals with MS has also been 
associated with unemployment as well as a lack of social support, depression, and increased 
reliance upon caregivers (Minden & Schiffer, 1990; Mohr, 2001; Bagert, Camplair, & Bourdette, 
2002).     
Reviews and meta-analyses have documented that cognitive dysfunction, measured by 
neuropsychological testing, is often seen in domains of working memory, cognitive processing 
speed, and executive control in persons with MS, but less so in intellectual functions and 
language skills (Prakash et al., 2007; 2008; Zakzanis, 2000; Bobholz, 2003; Rosti, Hamalainen, 
Koivisto, & Hokkanen, 2007; Schulz, 2006; Bagert, 2002).  In a review conducted by Bobholz 
and Rao (2003), cross-sectional research indicated that persons with MS performed significantly 
worse than healthy controls on neuropsychological tests in the domains of working memory, 
attention, and cognitive processing speed.  This trend was observed across a variety of 
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methodological paradigms for assessing cognition (Bobholz, 2003).  Further, persons with 
progressive MS generally performed worse on neuropsychological batteries than individuals with 
relapsing-remitting MS (Bobholz, 2003). 
Three meta-analyses examined the effects of multiple sclerosis on cognitive function.  In 
a 1997 meta-analysis, Wishart and Sharpe found significant deficits of similar magnitude in all 
examined domains of cognition in persons with MS.  Interestingly, in this quantitative review, 
disease course was not consistently associated with cognition (Wishart, 1997).  Conversely, a 
later meta-analysis (Zakzanis, 2000) reported that persons with chronic-progressive MS 
exhibited more impairment in the domain of executive function, whereas individuals with 
relapsing-remitting MS elicited greater memory impairment.  Recently, a third meta-analysis 
(Prakash et al., 2008) examined cognitive impairments in individuals with RRMS.  Overall, 
diagnosis of RRMS had a negative, moderate size effect on cognition (ES=-0.585) (Prakash, 
2008).  The domains of executive function and attention (namely cognitive processing speed) 
and general cognitive ability were more impaired than the domains of verbal functioning and 
language, concept formation, and reasoning in persons with RRMS (Prakash, 2008).   
Many different paradigms of neuropsychological tests have been implemented in order to 
examine different domains of cognitive function in persons with MS (Bobholz, 2003).  As 
identified in a recent meta-analysis (Prakash et al., 2008), the sub-domain of cognitive 
processing speed has been of particular interest to researchers and clinicians.  Two measures of 
cognitive processing speed, the Paced Auditory Serial Addition Test (PASAT) and the Symbol 
Digit Modalities Test (SDMT) have been utilized as screening tools for cognitive dysfunction in 
persons with MS (Rosti, 2007; Parmenter, Weinstock-Guttman, Garg, Munschauer, & Benedict, 
2007).   The PASAT is the sole measure of cognition in the Multiple Sclerosis Functional 
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Composite (Rosti, 2007). One study (Rosti et al., 2007) examined the ability of the PASAT (3.0 
second version) to detect cognitive impairment against a comprehensive neuropsychological 
battery of tests in 45 individuals with RRMS and 48 healthy controls.  The PASAT was quite 
accurate in detecting cognitive deficits in both MS and healthy controls (82% accuracy) as well 
as in persons with MS alone (74% accuracy) compared with the comprehensive battery of 
neuropsychological examinations (Rosti, 2007).  Another study (Parmenter et al., 2007) 
examined the effectiveness of the SDMT as a screening tool for cognitive impairment against the 
MACFIMS battery of neuropsychological tests in 100 individuals with MS and 50 healthy 
controls.  The SDMT classified cognitive dysfunction in persons with MS with 72% accuracy 
(Parmenter, 2007), a value similar to that of the PASAT (Rosti, 2007).  
 
TREATMENT OF COGNITIVE DYSFUNCTION IN MS 
Strategies for specifically treating cognitive impairment in multiple sclerosis have been 
implemented in two different approaches: pharmacological and non-pharmacological (Amato, 
Portaccio, & Zipoli, 2006).  Currently, there is no FDA-approved treatment for cognitive 
dysfunction in MS (Amato, 2006).  Disease-modifying agents (e.g., interferon beta-1a, interferon 
beta-1b, and glatiramer acetate) attempt to treat cognitive dysfunction indirectly, by preventing 
cerebral lesions or reducing cortical atrophy (Amato, 2006).  Overall, results from studies linking 
disease-modifying therapies to performance on neuropsychological tests have been 
disappointing, primarily due to poor external validity (Amato, 2006). 
  Additionally, pharmacological symptomatic treatments (e.g., L-amphetamine sulfate, 
memantine, modafinil, and donepezil) have been utilized to improve cognitive function in 
individuals with MS to mixed results.  L-amphetamine sulfate has been shown to enhance 
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memory in both animal models and humans (Morrow et al., 2009).  In a randomized, double-
blind, placebo-controlled trial, a 29-day oral dose of 30 mg of L-amphetamine sulfate (or 
placebo) was given to 151 individuals with MS who had documented cognitive impairment 
(Morrow, 2009).  Performance on a battery of neuropsychological tests was assessed as a 
measure of cognition both before and after treatment with L-amphetamine sulfate.  Results 
indicated that there were no significant improvements on subjective ratings of cognition or 
information processing speed in the L-amphetamine sulfate group (Morrow, 2009).   
Memantine, an effective treatment for Alzheimer’s disease, was also implemented in a 
randomized, double-blind, placebo-controlled trial with the aim of improving cognitive 
dysfunction in persons with MS who had a history of cognitive impairment (Stankoff, 2005).  54 
individuals received a titrated 12-week treatment course of memantine and 60 received a placebo 
over the same duration.  A battery of neuropsychological tests was administered both at baseline 
and completion of the 12-week period as a measurement of cognition (Stankoff, 2005).  There 
were no statistically significant results from any of the cognitive assessments over the duration of 
memantine therapy.   
Modafinil is a pharmacological agent that has also been thought to improve cognitive 
function in persons with MS (Amato, 2006; Lovera et al., 2010).  Modafinil is a stimulant of the 
central nervous system, and is utilized as a treatment for fatigue in MS (Lovera, 2010). Modafinil 
has been hypothesized to affect brain regions important in cognition (Lovera, 2010), although 
there has been no published research on its efficacy for treating cognitive impairment in MS 
(Amato, 2006). 
Recently, donepezil, an acetylcholinesterase inhibitor used to treat dementia in 
individuals with Alzheimer’s disease, has been examined as a potential treatment of cognitive 
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impairment in MS.  In a randomized, double-blind, placebo-controlled study, the effectiveness of 
donepezil was evaluated in a sample of 69 individuals with MS (Christodoulou et al., 2006).  
Participants received treatment for 24 weeks with either donepezil or a placebo and completed 
the Selective Reminding Test (a measure of verbal learning and memory) at both baseline and at 
the completion of the treatment course (Christodoulou, 2006).  Results indicated that patients 
receiving donepezil significantly improved memory function to a medium effect size compared 
with the placebo group (Christodoulou, 2006).  Results from other studies involving donepezil 
have been promising; however, more research is needed in larger samples of cognitively 
impaired individuals with MS (Amato, 2006).   
Non-pharmacological treatment of cognitive impairment in multiple sclerosis primarily 
involves cognitive rehabilitation.  Cognitive rehabilitation interventions are designed to either 
directly improve cognition or develop strategies to compensate for cognitive impairment 
(Bobholz, 2003).  Results from studies examining the effectiveness of cognitive rehabilitation in 
persons with MS have been largely disappointing, due to small sample sizes and methodological 
flaws (Amato, 2006; O’Brien, Chiaravalloti, Goverover, & DeLuca, 2008).  This line of research 
is in its infancy; however, alternative behavioral approaches for managing cognitive dysfunction 
in persons with MS have been identified, namely, exercise training. 
 
EXERCISE TRAINING AND COGNITION IN MS 
Exercise training might represent a behavioral approach for managing cognitive 
dysfunction in persons with multiple sclerosis, but this area has been understudied.  Indeed, there 
is emerging interest by researchers and clinicians in the effects of fitness (i.e., characteristics of 
an individual, reflecting aerobic capacity, muscular strength, balance, agility, etc.) and exercise 
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(i.e., planned behavior aimed towards improving an individual’s fitness) on cognition in 
individuals with MS.  To date, two studies have examined cardiorespiratory fitness (a presumed 
surrogate of aerobic exercise training) as a correlate of cognitive function in MS (Prakash et al., 
2007; 2010), and two randomized controlled trials have examined the effects of exercise training 
on cognition in persons with MS (Oken et al., 2004; Romberg, Virtanen & Ruutiainen, 2005).   
Prakash and colleagues (2007) examined cardiorespiratory fitness and cognition, as well 
as cortical activation patterns in 24 individuals with MS.  Cardiorespiratory fitness was assessed 
using a maximal incremental exercise test on a cycle ergometer in order to measure peak oxygen 
consumption (VO2) (Prakash, 2007).  Cognition was assessed using a battery of 
neuropsychological tests, as well as with the PVSAT, a visual administration of the PASAT 
(Prakash, 2007).  Results indicated that greater levels of cardiorespiratory fitness were 
significantly correlated with faster reaction time on the PVSAT and performance on the PASAT, 
as part of the neuropsychological battery (Prakash, 2007).  Additionally, higher VO2peak scores 
were associated with greater activation of the right inferior frontal gyrus and middle frontal gyrus 
(regions of the cerebral cortex), and less activation of the anterior cingulate cortex (Prakash, 
2007).   
In another study, Prakash and colleagues (2010) examined the relationship between 
cardiorespiratory fitness, white and grey matter integrity, and cognition in a sample of 21 persons 
with MS and 15 healthy controls.  Cardiorespiratory fitness was represented by peak oxygen 
consumption during a maximal incremental exercise test performed on a cycle ergometer.  
Participants also completed a battery of neuropsychological tests including the PASAT, SDMT, 
and a word generation task.  Finally, in order to evaluate white and grey matter integrity, 
participants underwent an MRI (Prakash, 2010).  Higher levels of cardiorespiratory fitness were 
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associated with better performance on a composite measure of processing speed in persons with 
MS, as well as with less lesion load volume and greater gray matter volume (Prakash, 2010).  
This finding suggests that cardiorespiratory fitness, cognition, and white and grey matter 
integrity are interrelated (Prakash, 2010).   
The effects of exercise training on cognition have also been examined in persons with 
MS.  One study employed a 6-month intervention consisting of a weekly yoga class, weekly 
aerobic exercise class, or wait-list control in 57 individuals with MS (Oken, 2004).  Participants 
were randomized to the yoga, aerobic exercise, or control group.  The yoga consisted of a 90 
minute session, once per week.  The aerobic exercise condition entailed group exercise on a 
stationary bicycle at the intensity of 2-3 (i.e., minimal exertion) on the Borg RPE scale (Oken, 
2004).  Sessions took place once per week, and home exercise was encouraged (Oken, 2004).  
Periodically, participants were given the option of exercising on a Swiss ball rather than cycling 
(Oken, 2004).  Cognition was assessed at both baseline and following the 6th month of the 
intervention using a battery of neuropsychological tests.  Following the completion of the 
intervention, neither the yoga group nor the exercise group displayed significant improvement in 
any cognitive measure compared with the wait-list control group (Oken, 2004).   
One concern regarding the results of this study is that the aerobic exercise condition took 
place at an extremely light intensity (e.g., 2-3 on the Borg RPE scale) as well as only once per 
week, such that the maximal benefits of exercise training on cognition in persons with MS could 
not be realized.  Participation in the weekly classes of either experimental condition was quite 
low (65%), further curtailing the potentially beneficial effects of aerobic exercise or yoga on 
cognition in persons with MS.  Moreover, the home exercise that was encouraged to participants 
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was unsupervised, potentially compromising the possible benefits of the aerobic exercise 
intervention on cognition.   
Another study involved 95 persons with MS being randomized into either a 6-month long 
exercise training intervention or wait-list control group (Romberg, 2005).  The exercise training 
intervention consisted of five resistance training sessions and five aerobic training sessions in the 
first 3 weeks of the intervention, followed by 23 weeks of a prescribed home exercise regimen 
(Romberg, 2005).  This program, explained by physiotherapists, entailed mainly resistance 
exercise (e.g., suggested to take place 3-4 times per week) with additional sessions of aerobic 
exercise (e.g., suggested to take place once per week) (Romberg, 2005).  Participants were 
encouraged via phone to adhere to the home exercise program on four separate occasions over 
the 6-month intervention (Romberg, 2005).  Cognition was assessed at both baseline and after 
the end of the intervention period with the PASAT.  Processing speed did not significantly 
improve in persons with MS following the exercise intervention (Romberg, 2005).   
One concern about the results of this randomized controlled trial is that physical function 
did not significantly improve in the exercise group over the 6 month period (ES = −0.19), 
indicating that the exercise prescription was ineffective (Romberg, 2005). Additionally, physical 
function was assessed through a self-reported measure of quality of life (MSQOL-54), rather 
than with an objective performance measure.  No outcome measures of physical fitness (e.g., 
muscular strength or aerobic capacity) were taken prior to or following the intervention.  A 
possible factor for the lack of improvement of physical function (and possibly cognition) was the 
under-regulation of the exercise training program from weeks 4-26 (i.e., only four instances of 
contact between physiotherapists and participants during a 23-week long intervention). 
 16 
Such disappointing results from training studies highlight the importance of considering 
the well-established gerontological literature (Hillman, Erickson & Kramer, 2008) as a way of 
better informing examinations of fitness, exercise training, and cognition in MS. 
 
FITNESS AND EXERCISE TRAINING ON COGNITION IN OLDER ADULTS 
Cognitive impairment too, is common, debilitating, and poorly managed in older adults, 
and more importantly, there is a wealth of literature indicating that fitness and exercise training 
are associated with better cognitive performance in this population.  Mild cognitive impairment 
(MCI) is thought to affect nearly 45% of adults over the age of 65 in the United States (Bassuk, 
Wypij, & Berkman, 2000), and approximately 15% of individuals with MCI will develop 
dementia (Ritchie, 2004).  Dementia has been associated with decreased social functioning, and 
importantly, mortality (Ritchie, 2004).  The prevalence of dementia in the United States is 
currently estimated at 3.4 million individuals (Plassman et al., 2007).  
In general, older adults commonly experience cognitive deficits in domains of attention, 
executive control, and memory (Hawkins, Kramer, & Capaldi, 1992; Kramer et al., 1999; Grady 
& Craik, 2000).  These decrements can have profound effects on activities of daily life.  
Cognitive impairment in older adults has been strongly associated with functional decline (i.e., 
difficulty completing daily tasks including self-care and basic household chores) (Stuck et al., 
1999).  Further, cognitive impairment has been identified as a major risk factor for increased 
home care, hospitalization, admission into a nursing home, and mortality (Bassuk, 2000).  One 
longitudinal epidemiological study of community-dwelling older adults (Bassuk et al., 2000) 
found that both mild and severe cognitive impairment were strongly associated with an increased 
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risk of mortality.  Further, those who experience cognitive decline, independent of the initial 
extent of cognitive dysfunction, incur an additional risk of mortality (Bassuk, 2000). 
There is no FDA-approved pharmacological treatment for cognitive impairment in older 
adults, and trials of cholinesterase inhibitors (e.g., donepezil) have been disappointing in this 
population (Gauthier et al., 2006).  Non-pharmacological cognitive training interventions 
specifically designed to target one specific domain of cognition (for example, attempting to 
improve visual search strategies to enhance executive control) have been successful in laboratory 
environments, but seem to lack generalizability to everyday situations (Bell et al., 2002). 
Fitness and exercise training have been identified as a means to improve cognition in 
older adults (Kramer, 1999).  Early exercise training interventions illustrated that older adults, 
following participation in an exercise program, demonstrated better performance on cognitive 
tasks compared to controls (Dustman et al., 1984; Hawkins, 1992).  Two major meta-analyses 
have been published on exercise and cognition in older adults.  One meta-analysis reported that 
exercise training in older adults was associated with overall better performance on cognitive 
tasks with an average effect size of 0.478 standard deviations (Colcombe & Kramer, 2003).  
Interestingly, the moderator analysis indicated that combined exercise training (both strength and 
aerobic training) was associated with greater improvements in cognition than aerobic training 
alone (Colcombe, 2003).  The other meta-analysis reported that exercise training (consisting of a 
variety of aerobic, strength, and mobility-related exercises) was associated with improved 
cognitive performance in older adults with documented cognitive impairment, with an average 
effect size of 0.59 standard deviations (Heyn, Abreu, & Ottenbacher, 2004).   
These findings collectively suggest that cardiorespiratory fitness, as well as other 
domains of fitness (e.g., muscle strength, mobility/balance), have the potential for independent 
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contributions towards combating cognitive impairment in older adults, and perhaps multiple 
sclerosis.  The gerontology literature provides a backdrop for the proposed study of fitness and 
cognition in MS by indicating that different types of fitness and modes of training are important 
when developing interventions to maximize cognitive benefits.  
 
SUMMARY 
Multiple sclerosis (MS) is a non-traumatic neurodegenerative disease, characterized by 
immune-mediated, multi-focal demyelination of white matter in the central nervous system.  
There is increasing evidence that cognitive impairment is debilitating, highly prevalent, and 
poorly managed in persons with MS.  There are no FDA-approved treatments for cognitive 
impairment in MS, and trials of pharmacological agents and proposed strategies for cognitive 
rehabilitation have been conflicting and disappointing.  Exercise training has been identified as a 
possible behavioral approach for managing cognitive dysfunction in MS, largely based on 
literature of fitness, exercise training, and cognition in older adults.  The proposed study will 
examine relationships among cardiorespiratory fitness, muscle strength, and balance, as 
components of fitness and cognitive function in persons with MS.  This examination of physical 
fitness will inform the development of subsequent exercise training interventions aimed at 
improving cognition in persons with MS.  
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Chapter 3—Methods 
PARTICIPANTS 
31 ambulatory persons (i.e., ability to walk independently, or with minimal assistance) 
with a definite diagnosis of MS between the ages of 18 and 54 (males 18-44, and females 18-54), 
and relapse-free for 30 days, were recruited along with 31 healthy controls (matched by age, 
height, weight, and gender).  All participants lived within a 90 mile radius of Champaign-
Urbana, and persons with MS were identified from a pre-existing database consisting of 
participants from previous studies conducted by our laboratory. Healthy controls were contacted 
via the provision of public e-mail postings, advertising a study of physical fitness and cognition.  
Participants were contacted via phone or e-mail and a researcher explained the basic protocol of 
the study.  If the contacted individual was interested in the study, screening and scheduling took 
place via telephone conversation, during which, each participant was notified of confidentiality 
procedures, as well as payment information following the completion of the study protocol. 
Inclusion criteria involved a “no” response on all items of the Physical Activity Readiness 
Questionnaire (PAR-Q; Thomas, Reading, & Shephard, 1992).  If only one “yes” response was 
given, participants provided a physician’s approval in order to engage in the study.  More than 
one “yes” on the PAR-Q resulted in exclusion from the study. A total of 63 persons with MS 
were contacted with 51 expressing interest in participating. 47 persons were screened, 6 persons 
did not meet inclusion criteria, and 10 individuals cancelled their testing session (for reasons 
unrelated to testing), resulting in a subsample of 31 persons with MS. 101 healthy controls were 
contacted, with 61 expressing interest. Of the 61 who were interested in participation, 32 were 
matched by age, sex, height, and weight to persons with MS, and one matched control did not 
meet inclusion criteria, resulting in a final subsample of 31 matched controls.  
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PRIMARY MEASURES 
Fitness 
Aerobic Capacity 
Aerobic capacity was measured as peak oxygen consumption (VO2peak) using an 
incremental exercise test on an electronically-braked, computer-driven cycle ergometer (Lode 
BV, Groningen, The Netherlands) and an open-circuit spirometry system (TrueOne, Parvo 
Medics, Sandy, UT) for analyzing expired gases. Initially, participants were fitted to the cycle 
ergometer, and the testing procedures, along with instructions for reporting rating of perceived 
exertion (RPE) were provided by an investigator. After being fitted with a mouthpiece (Hans 
Rudolph, Kansas City, MO) for collecting expired gases, the participants performed a 3-minute 
warm-up at 0 watts. The initial work rate for the exercise test was 0 watts, and the work rate 
continuously increased at a rate of 15 watts/minute until the participant reached volitional 
fatigue. With the use of the open-circuit spirometry system, VO2, respiratory exchange ratio 
(RER), and work rate were measured continuously and expressed as 20-second averages. Heart 
rate (HR) was displayed using a Polar heart rate monitor (Polar Electro Oy, Finland), and HR 
and RPE were recorded each minute during the test. VO2peak was expressed in ml·kg-1·min-1 
based on highest recorded 20-second VO2 value when two of three criteria were satisfied: (1) 
RER ≥1.10; (2) peak HR within 10 beats per minute of age-predicted maximum (i.e., ~1 SD); or 
(3) peak RPE ≥17. 
Balance 
Balance was based upon assessments of the motion of the center of pressure (COP). COP 
was quantified with a force platform (Kistler model 928/B11, AMTI, Inc.) and data were 
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collected with a sample frequency of 100 Hz and conditioned with a 4th order Butterworth low 
pass filter with a cutoff frequency of 5 Hz. Participants stood without shoes on the force platform 
and maintained a quiet upright stance; use of assistive devices (i.e., cane) was prohibited during 
the balance protocol. Rather, two spotters were present in order to minimize any risk of falls, and 
this was consistent over the trial. We sampled a total of two 30 second trials under eyes-open 
conditions, as per reliability recommendations. Participants were given a short break between 
each trial. The amount of motion of the COP was indexed by a 95% confidence ellipse, and 
balance was expressed as the total area (cm2) of the 95% confidence ellipse of the COP, 
averaged across both trials. 
Muscular Strength 
Bilateral isometric knee extensor and flexor peak torque was measured using a Humac 
Norm Isokinetic dynamometer (CSMI Solutions, Stoughton, MA). Participants were positioned 
on the dynamometer according to the manufacturer's recommendation. Briefly, the axis of 
rotation of the machine aligned with the lateral epicondyle of the femur. The calf pad against 
which the participant exerted force was positioned halfway between the lateral malleolus of the 
fibula and lateral epicondyle of the femur, and securely attached using straps. A belt was placed 
over the torso region to minimize movement during the test. We used an anatomical reference 
position of 90° knee flexion, and isometric torque was assessed at joint angles of 45°, 60°, and 
75°, respectively. Peak torque was obtained by having the participant perform 3 maximal 
contractions with the knee extensors for 5 seconds, which was immediately followed by a 5 
second maximal contraction with the knee flexors; 3 sets were performed, per knee. There was 
not a rest period between contractions within a set, and the rest period between sets was 2 
minutes. The highest recorded peak torque for the strongest leg was used as a measure of knee 
 22 
extensor and flexor isometric strength, and expressed as strength per body weight (n·m·kg-1). Our 
rationale for examining the stronger leg only was that in persons with MS, measuring peak 
isometric torque in the weaker leg might reflect disease pathology along with physiological de-
training, whereas peak torque in the stronger leg would primarily reflect detraining with a lesser 
disease pathology component. 
Cognition 
Both the Paced Auditory Serial Addition Test (PASAT) and Symbol Digit Modalities 
Test (SDMT) were utilized as neuropsychological measures of cognition.  The PASAT 3” 
version is the sole indicator of cognition in the Multiple Sclerosis Functional Composite (MSFC) 
(Rosti et al., 2007) and is used to assess cognitive processing speed and flexibility.  In the 3” 
version of the PASAT, a series of random single digit numbers are presented at the rate of 1 
every 3 seconds via audio recording.  Participants are explicitly instructed to orally report the 
sum of the last two numbers that were presented on the recording.  Prior to testing, the 
experimenter gave an example of how to perform the task correctly, ensuring that the participant 
understood not to give running totals, but rather, separate sums of the two most recent numbers 
presented on the tape.  Up to three practice trials, consisting of 11 random numbers that were 
presented at the rate of 1 every 3 seconds, were completed by the participant prior to live testing.  
During the actual test, an uninterrupted series of 61 random numbers were presented at the same 
rate.  The main outcome measure of the PASAT was the number of correct responses given out 
of a possible 60.   
The written version of the SDMT (Smith, 2010) was used as an assessment of cognitive 
processing speed.  In this task, a series of 9 random geometric symbols are paired with the 
numbers 1 through 9 in a key.  Below the key, a randomized list of 10 symbols with blank boxes 
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underneath serve as practice items, followed by a similar list of 110 symbols appearing in a 
random order.  Participants were read instructions in order to complete the test correctly, and 
were instructed to write the number that corresponds to a given symbol in an empty box, 
according to the way symbols are paired with numbers in the key.  Participants completed the 10 
practice boxes, while the experimenter ensured the absence of errors.  Following the practice 
trial, participants were given 90 seconds to fill in as many empty boxes as possible, in order, 
without skipping any.  The main outcome measure of the SDMT was the number of correctly 
written numbers in the 90 second period monitored by the experimenter. 
 
PROTOCOL 
For each group (MS or healthy control), the experimental protocol involved two sessions 
of testing on the University of Illinois at Urbana-Champaign campus, with a week-long period 
separating each session. The order of assessments during each session was intentionally designed 
to minimize fatigue.  The flow of testing is represented by Figure 1. Prior to any testing, all 
participants provided written informed consent approved by a University Institutional Review 
Board.  During the first testing session, both neuropsychological assessments were administered, 
followed by balance testing.  Finally, muscle strength was assessed during this session.   
All participants began the second testing session by completing a short battery of 
questionnaires, consisting of a demographics form, and participants with MS further completed 
the Patient Determined Disease Steps scale (PDDS) (developed as an inexpensive surrogate to 
the Expanded Disability Status Scale; EDSS; Kurtzke, 1983). Following the completion of 
questionnaires, all participants underwent an incremental exercise test on a cycle ergometer to 
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measure peak oxygen consumption.  Upon completion of both testing sessions, participants were 
paid $30.  
 
STATISTICAL ANALYSES 
Data were analyzed in PASW Statistics version 18.0 (SPSS Inc., Chicago, IL).  We first 
examined differences between MS and control groups in age, height, and weight using 
independent-samples t-tests. Based on previous work (e.g., Prakash et al., 2007; Prakash et al., 
2010) and improved reliability, we next created z-scores in PASW for the PASAT and SDMT, 
and combined the z-scores into a composite score for cognitive processing speed (mean of z-
scores for PASAT and SDMT). Independent samples t-tests were then conducted to detect 
differences between MS and control groups in cognitive performance and fitness. We examined 
group differences in performance on both the PASAT and SDMT, as well as the composite 
cognitive processing speed z-score, to establish differences in both raw performance and the 
composite z-score. The magnitude of group differences in cognitive and fitness variables 
between groups was expressed as Cohen’s d (i.e., difference in mean scores between groups 
divided by the pooled standard deviation; Cohen, 1985). Values for Cohen’s d of .2, .5, and .8 
were interpreted as small, moderate, and large, respectively (Cohen, 1985). Bivariate correlations 
were then performed for all measures of fitness and the composite cognitive processing speed 
variable in the overall sample, and in the MS and healthy control subsamples, separately.  Values 
for correlation coefficients of .1, .3, and .5 were interpreted as small, moderate, and large, 
respectively (Cohen, 1985). We then performed hierarchical linear regression analysis for 
examining fitness as a mediator of group differences in cognitive processing speed. This was 
undertaken by regressing cognitive processing speed on group in Step 1 and then adding fitness 
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variables that differed between groups and correlated with cognitive processing speed overall in 
Step 2. We compared the β-coefficient for group between Step 1 and Step 2 to examine if fitness 
explained group differences in cognitive processing speed. We further compared β-coefficients 
for the fitness variables for identifying the independent contributions for explaining differences 
in cognition.  
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Chapter 4—Results 
SAMPLE 
Descriptive statistics for the 31 persons with MS and 31 controls are reported in Table 1. 
There were no statistically significant differences in age (t = 0.57, p = 0.57), height (t = −.11, p = 
0.91), or weight (t = 0.95, p = 0.35) between the groups, and the groups had an identical 
distribution of sex (27 females and 4 males). In the MS subsample, 29 participants (94%) had a 
relapsing-remitting disease course, and 2 participants (6%) had secondary-progressive MS, and 
the mean duration of MS was 8.6 (SD=6.3) years. The sample of persons with MS further had 
minimal disability based on median PDDS scores, and this was expected given the demanding 
nature of fitness tests. 
 
GROUP DIFFERENCES IN COGNITION AND PHYSICAL FITNESS 
The descriptive statistics for the two measures of cognitive performance and three 
domains of physical fitness for the MS and control subsamples are presented in Table 2. There 
were statistically significant differences between groups in PASAT performance (t = −2.137, p = 
.037) and SDMT performance (t = −2.690, p = .009). The effect sizes for the PASAT and SDMT 
were −0.53 and −0.65, respectively, indicating that persons with MS had moderately slowed 
cognitive processing speed compared with matched controls. There further were significant 
differences in aerobic capacity (t = −2.986, p = .004, d = −0.72) and balance (t = 4.126, p < .001, 
d = 0.91) between persons with MS and matched controls. The effect sizes of −0.72 and 0.91 
indicated that persons with MS had a moderately reduced VO2peak and a largely worse balance 
compared with matched controls, respectively. There were no statistically significant differences 
between persons with MS and matched controls in knee extensor strength (t = −0.559, p = .578) 
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and a nearly significant difference in knee flexor strength (t = −1.589, p =.117) for the stronger 
leg, respectively; and this pattern was consistent with results from other studies that reported no 
differences in knee extensor strength but significant differences in knee flexor strength between 
persons with MS and healthy controls (Kalron, Achiron, & Dvir, 2011; Chung, Remelius, Van 
Emmerick, & Kent-Braun, 2008; Lambert, Archer, & Evans, 2001).  
 
CORRELATIONS AMONG PHYSICAL FITNESS AND COGNITION 
Correlations among cognitive and physical fitness variables for the overall, MS, and 
control samples are reported in Table 3. In the overall sample, cognitive processing speed was 
significantly associated with aerobic capacity (r = .426, p = .001) and balance (r = −.516, p < 
.001), respectively. Cognitive processing speed was not associated with either measure of 
muscular strength. Within the MS subsample, cognitive processing speed was significantly 
associated with aerobic capacity (r = .442, p = .013) and balance (r =−.520, p = .003) and this is 
presented using scatter plots in Figure 2. Cognitive processing speed was not associated with 
either measure of muscular strength in persons with MS. Within the matched control subsample, 
cognitive processing speed was not significantly associated with aerobic capacity (r = .310, p = 
.090), balance (r = −.038, p = .839), nor either measure of muscular strength.  
 
REGRESSION ANALYSIS 
The results for the hierarchical regression analysis are in Table 4. Group (B = .589, SE B 
= .215, β = .333) explained a statistically significant (F(1, 60) = 7.487, p = .008) portion of 
variance in cognitive processing speed (R2 = .111) in Step 1. In Step 2 of the model, the β for 
group became attenuated and non-significant (β = .046, p = .712) and aerobic capacity (B = .030, 
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SE B = .013, β = .273) and balance (B = −.109, SE B = .034, β = −.402) explained a statistically 
significant (F(3, 58) = 9.898, p < .001) amount of variance in cognitive processing speed (R2 = 
.339). We did not include muscular strength in the regression analysis since there were no 
significant group differences in muscular strength, and muscular strength was not associated with 
cognitive processing speed in the overall, MS, or control samples.  
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Chapter 5—Discussion 
This study examined the relationships among aerobic capacity, balance, and muscular 
strength with cognitive processing speed in 31 persons with MS and 31 controls matched by age, 
height, weight, and sex. The primary novel findings were that (a) there were significant 
differences between persons with MS and controls in aerobic capacity, balance, and cognitive 
processing speed; (b) in both the overall, and MS subsamples, aerobic capacity and balance were 
significantly associated with composite processing speed, and these associations were both 
moderate-to-strong in magnitude; (c) aerobic capacity and balance accounted for differences in 
cognitive processing speed between persons with MS and controls; and (d) aerobic capacity and 
balance made significant, independent contributions towards cognitive processing speed. 
Such results are important for informing exercise training interventions for improving 
slowed cognitive processing speed in persons with MS. To date, only two RCTs have examined 
the effects of exercise training on cognition in persons with MS (Oken et al., 2005; Romberg et 
al., 2004). Both interventions had methodological concerns (i.e., relied heavily upon 
unsupervised, home-based exercise; extremely light intensity exercise prescription, such that 
physical fitness did not improve over the duration of the intervention; self-report measures of 
physical function, rather than objective measures of fitness) and cognition did not improve 
following either intervention (Oken et al., 2004; Romberg et al., 2005). Regression analyses from 
the current investigation identified aerobic capacity and balance as mediators of differences in 
cognitive processing speed between MS and control groups. Both domains of fitness represent 
potential targets for improving slowed cognitive processing speed in persons with MS, thus, 
future exercise training interventions should aim to improve both aerobic capacity and balance as 
an approach to enhance cognitive processing speed in this population. Importantly, such 
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interventions in persons with MS should be on par with the scientific rigor of exercise training 
interventions for improving cognition carried out in older adults (Motl et al., 2011). 
Aerobic capacity and balance were both significantly associated with cognitive 
processing speed in the overall sample, and persons with MS, respectively, and these correlations 
were of moderate-to-strong magnitude (Cohen, 1985). Further, aerobic capacity and balance 
made significant, independent contributions for explaining differences in cognitive processing 
speed between MS and control groups. This is of particular importance as exercise has been 
proposed to reverse physiological deconditioning (i.e., reductions in aerobic capacity, muscle 
strength, and balance) in persons with MS (Motl, Goldman, & Benedict, 2010). The current 
results extend this proposition to include cognitive domains given that aerobic capacity and 
balance (surrogates of exercise training) were significantly associated with cognitive processing 
speed, such that increasing physical fitness might mitigate cognitive impairment in persons with 
MS.  
There was not a significant difference in knee extensor strength between groups and there 
was nearly significant difference between groups in knee flexor strength, and this pattern was 
consistent with previous findings (Kalron et al., 2011; Chung et al., 2008; Lambert et al., 2001). 
Additionally, muscular strength was not associated with cognitive processing speed in the 
overall, MS, or control samples, respectively. Collectively, these data did not support our 
hypotheses. By extension, knee extensor and flexor strength would seemingly not be ideal targets 
for improving cognitive processing speed in persons with MS. This was not expected, as a 
seminal meta-analysis (Colcombe, 2003) reported that combined aerobic and resistance training 
is associated with improved cognition in older adults (a population who experiences cognitive 
impairment in domains similar to persons with MS). One potential reason for the lack of an 
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association between muscular strength and cognitive processing speed in the current study is that 
muscular power, as opposed to strength, might be associated with faster cognitive processing 
speed in persons with MS. This is based on several studies that have reported that knee extensor 
power is associated with better cognition in older adults (Petrella, Miller, & Cress, 2004; Liu-
Ambrose, Nagamatsu, Graf, Beattie, Ashe, & Handy, 2010). However, in the current study, both 
measures of muscular strength were strongly related to aerobic capacity in the overall, MS, and 
control subsamples, respectively. Further, knee extensor strength was significantly and strongly 
associated with knee flexor strength in the overall, MS, and control subsamples, respectively. 
Collectively, these associations are consistent with a large body of literature of muscular strength 
and aerobic fitness in other populations (e.g., Millet, Jaouen, Borrani, & Candau, 2002). In 
resistance training studies in persons with MS, isometric leg strength is indeed a commonly 
reported outcome measure (e.g., White, McCoy, Castellano, Gutierrez, Stevens, Walter, & 
Vandenborne, 2004; Gutierrez, Chow, Tillman, McCoy, Castellano, & White, 2005; Dalgas et 
al., 2009), and our protocol was consistent with such methodologies. However, it should be 
noted that there have been no cross-sectional investigations or RCTs specifically examining 
muscular strength or muscular power on cognition in persons with MS to establish a gold-
standard for outcomes associated with resistance exercise. 
One study reported that aerobic capacity was associated with increased white and grey 
matter integrity and better cognitive processing speed in persons with MS (Prakash et al., 2010). 
By extension, the associations among aerobic capacity, balance, and cognitive processing speed 
in persons with MS warrant further exploration into the possible neuroprotective effects of 
physical fitness, as brain atrophy (e.g., reduced third ventricular width, brain parenchymal 
volume, etc.) has been predictive of slowed cognitive processing speed in persons with MS 
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(Benedict et al., 2006). Future exercise training interventions might consider including imaging 
protocols (i.e., MRI) to assess potential preservation of CNS tissue in response to improved 
aerobic capacity and balance in persons with MS.  
Strengths of the current investigation include the objective measurement of multiple 
domains of fitness, inclusion of valid neuropsychological measures of cognitive processing 
speed, and inclusion of controls matched by age, height, weight, and sex. One limitation of the 
study is the cross-sectional nature of this investigation, as it does not indicate causality between 
measures of physical fitness and cognitive processing speed.  Indeed, cognitive impairment 
might influence participation in activities aimed to increase physical fitness, as much as physical 
fitness influences cognitive processing speed. Our sample was primarily female (87%), with a 
disproportionately larger ratio of females than males compared with the overall gender bias of 
the disease (i.e., females are 2-3 times more likely than males to have MS; Noonan et al., 2010). 
Finally, this study was advertised as an examination of physical fitness and cognition to both 
persons with MS and controls, and there might have been an upward bias of participation in 
exercise behavior in the overall combined sample. However, post-hoc independent samples t-
tests indicated that there was not a significant difference in self-reported exercise sessions per 
week (t = −1.133, p = .131) between persons with MS and matched controls.  
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Chapter 6—Conclusions 
Cognitive impairment, particularly slowed cognitive processing speed, is prevalent, 
disabling, and poorly-managed in persons with MS. Overall, there were significant differences in 
aerobic capacity, balance, and cognition between persons with MS and controls matched by age, 
sex, height, and weight. Aerobic capacity and balance were significantly associated with 
cognitive processing speed in persons with MS, and these associations were both moderate-to-
strong in magnitude. Further, aerobic capacity and balance accounted for differences in cognitive 
processing speed between persons with MS and controls and made significant, independent 
contributions for explaining such differences in cognitive processing speed. Such results are 
important for informing future exercise training interventions such that enhancing aerobic 
capacity and balance, but not muscular strength, represent targets for improving slowed cognitive 
processing speed in persons with MS. 
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Chapter 7—Tables and Figures 
Figure 1: Flow of Testing 
 
 
Initial Contact 
Description of Protocol, Screening, Scheduling 
Exclude: non-
ambulatory, out of age 
range, ≥ 2 “yes” 
responses on PAR-Q 
Testing Session 1: 
1. Informed Consent 
2. SDMT and PASAT 
3. Balance Testing 
4. Muscle Strength Testing 
Testing Session 2: 
1. Questionnaires 
a. Demographics, *PDDS 
2. Incremental Exercise Test on Cycle Ergometer 
3. Payment 
 
*Persons with MS only 
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Table 1: Demographic Characteristics of 31 persons with MS and 31 healthy controls 
matched by age, sex, height, and weight. 
 
Variable MS (n=31) Controls (n=31) 
Age (years) 43.4 (7.7) 42.4 (7.5) 
Sex (n,% female) 27/31, 87.1% 27/31, 87.1% 
Height (cm) 170.8 (8.7) 171.0 (8.6) 
Weight (kg) 75.2 (16.4) 71.5 (13.5) 
MS Type (n, % RRMS) 29/31, 93.5% - 
MS Duration (years) 8.6 (6.3) - 
PDDS Score (median, 
range) 
2 (0-5) - 
Note: Data are presented as mean (SD) unless noted otherwise; RRMS=Relapsing-remitting 
multiple sclerosis; PDDS=Patient-determined disease steps  
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Table 2: Cognitive performance and physical fitness data for 31 persons with MS and 31 
healthy controls matched by age, sex, height, and weight 
 
Variable MS (n=31) Controls (n=31) 
PASAT Performance 44.6 (12.2) 49.9 (6.5) 
SDMT Performance 51.7 (13.5) 59.5 (8.9) 
VO2peak (ml/kg/min) 23.5 (6.4) 29.3 (8.8) 
95% COP Ellipse (cm2) 5.2 (3.9) 2.2 (1.5) 
Maximal Knee Extensor 
Strength (Strong) (n·m/kg) 2.1 (0.5) 2.2 (0.5) 
Maximal Knee Flexor 
Strength (Strong) (n·m/kg) 0.5 (0.2) 0.6 (0.2) 
Note: Data are presented as mean (SD); PASAT=Paced Serial Auditory Addition Test; 
SDMT=Symbol Digit Modalities Test; COP=Center of Pressure; 
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Table 3a: Correlations among variables for the overall sample of 31 persons with MS and 
31 healthy controls matched by age, sex, height, and weight 
 
Overall Sample (n=62) 
Variable 1.  2.  3.  4.  5.  
1. CPS -     
2. VO2peak .43* -    
3. 95% COP Ellipse -.52* -.34* -   
4. Maximal KE Strength (Strong) .14 .56* -.19 -  
5. Maximal KF Strength (Strong) .22 .70* -.20 .64* - 
Note: * p<.05 with 2-tailed test; CPS=Cognitive Processing Speed; COP=Center of Pressure; 
KE=Knee Extensor; KF=Knee Flexor 
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Table 3b: Correlations among variables for 31 persons with MS 
 
MS (n=31) 
Variable 1.  2.  3.  4.  5.  
1. CPS -     
2. VO2peak .44* -    
3. 95% COP Ellipse -.52* -.38* -   
4. Maximal KE Strength (Strong) .03 .58* -.23 -  
5. Maximal KF Strength (Strong) .13 .52* -.19 .62* - 
Note: * p<.05 with 2-tailed test; CPS=Cognitive Processing Speed; COP=Center of Pressure; 
KE=Knee Extensor; KF=Knee Flexor 
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Table 3c: Correlations among variables for 31 healthy controls matched by age, sex, height, 
and weight 
 
Controls (n=31) 
Variable 1.  2.  3.  4.  5.  
1. CPS -     
2. VO2peak .31 -    
3. 95% COP Ellipse -.04 -.01 -   
4. Maximal KE Strength (Strong) .31 .58* -.11 -  
5. Maximal KF Strength (Strong) .25 .79* -.02 .65* - 
Note: * p<.05 with 2-tailed test; CPS=Cognitive Processing Speed; COP=Center of Pressure; 
KE=Knee Extensor; KF=Knee Flexor 
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Table 4: Summary of hierarchical regression analysis for predicting cognitive processing 
speed in persons with MS (n=31) and controls (n=31) 
 
Variable B SE B β 
Step 1    
      Group 0.59 0.22   0.33* 
Step 2    
      Group 0.08 0.22 0.05 
      VO2peak 0.03 0.01   0.27* 
      Balance            −0.11 0.03 −0.40* 
Note: R2=.11 for Step 1; ∆R2=.23 for Step 2 (p<.05, two-tailed test). *p<.05 with one-tailed test. 
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Figure 2a: Scatter plot of composite cognitive processing speed (CPS) performance and 
VO2peak in 31 persons with MS, along with line of best fit and 95% confidence interval. 
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Figure 2b: Scatter plot of composite cognitive processing speed (CPS) performance and 
balance in 31 persons with MS, along with line of best fit and 95% confidence interval.  
 
 
Note: COP=Center of Pressure 
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